Inhibiting the FGF pathway with brivanib (a first-class dual inhibitor of VEGR2-3/FGFR1-2-3) in mice with pancreatic neuroendocrine tumors has resulted in promising activity after failure to anti-VEGF treatment [140]. This evidence concerns the gene FGFR1 and pancreatic neuroendocrine tumor.